GIANT CELL ARTERITIS OF THE ELDERLY
(TEMPORAL ARTERITIS)
Giant cell arteritis (GCA) is a large vessel vasculitis that primarily affects white patients over the age of 50, often affecting the extracranial arteries.
Patients frequently manifest new onset of headache, which is continuous, scalp or temporal artery tenderness, jaw claudication, visual disturbances, fatigue, and arthralgias.
Patients can have an insidious or explosive onset of disease and can manifest primarily cranial or constitutional symptoms.
Blindness occurs in about 15% of patients with GCA, even with appropriate therapy, and can occur at disease onset.
The diagnosis of GCA should be confirmed with a superficial temporal artery biopsy. Whether or not bilateral biopsies should be obtained initially remains an area of controversy, because a few cases have been reported in which the symptomatic temporal artery biopsy was negative but the
asymptomatic contralateral artery demonstrated arteritis.
Anemia and elevated acute phase reactants are commonly seen in patients with GCA.
Large vessel disease, similar to that seen in TA, has been reported in GCA. Aortitis is one of the most common manifestations of large vessel involvement in patients with GCA and leads to an increased risk of aortic aneurysm and subsequent dissection and rupture. Given this potential catastrophic complication, it has been suggested that GCA patients undergo yearly surveillance with chest radiography to look for aortic enlargement, but the potential impact of this intervention on outcomes in GCA remains speculative.
Glucocorticoids are the cornerstone of therapy in GCA. Patients often experience disease relapses with steroid tapering, but other immunosuppressive agents overall have not demonstrated steroid-sparing activity in GCA. Although many patients with relapsing disease are still given trials of
other immunosuppressive agents, given the toxicities associated with long-term steroid use, most patients continue to require steroid therapy for maintaining disease remission.
Polymyalgia rheumatica (PMR), a syndrome characterized by pain and stiffness in the muscles of the neck, shoulder girdle, and hip girdle with other signs and symptoms of systemic inflammation, is associated with GCA. However, not all patients with GCA manifest PMR symptoms, and not
all patients with PMR develop GCA. However, because the prevalence of GCA is higher in patients with PMR, they should be educated regarding signs and symptoms of GCA.
(TEMPORAL ARTERITIS)
Giant cell arteritis (GCA) is a large vessel vasculitis that primarily affects white patients over the age of 50, often affecting the extracranial arteries.
Patients frequently manifest new onset of headache, which is continuous, scalp or temporal artery tenderness, jaw claudication, visual disturbances, fatigue, and arthralgias.
Patients can have an insidious or explosive onset of disease and can manifest primarily cranial or constitutional symptoms.
Blindness occurs in about 15% of patients with GCA, even with appropriate therapy, and can occur at disease onset.
The diagnosis of GCA should be confirmed with a superficial temporal artery biopsy. Whether or not bilateral biopsies should be obtained initially remains an area of controversy, because a few cases have been reported in which the symptomatic temporal artery biopsy was negative but the
asymptomatic contralateral artery demonstrated arteritis.
Anemia and elevated acute phase reactants are commonly seen in patients with GCA.
Large vessel disease, similar to that seen in TA, has been reported in GCA. Aortitis is one of the most common manifestations of large vessel involvement in patients with GCA and leads to an increased risk of aortic aneurysm and subsequent dissection and rupture. Given this potential catastrophic complication, it has been suggested that GCA patients undergo yearly surveillance with chest radiography to look for aortic enlargement, but the potential impact of this intervention on outcomes in GCA remains speculative.
Glucocorticoids are the cornerstone of therapy in GCA. Patients often experience disease relapses with steroid tapering, but other immunosuppressive agents overall have not demonstrated steroid-sparing activity in GCA. Although many patients with relapsing disease are still given trials of
other immunosuppressive agents, given the toxicities associated with long-term steroid use, most patients continue to require steroid therapy for maintaining disease remission.
Polymyalgia rheumatica (PMR), a syndrome characterized by pain and stiffness in the muscles of the neck, shoulder girdle, and hip girdle with other signs and symptoms of systemic inflammation, is associated with GCA. However, not all patients with GCA manifest PMR symptoms, and not
all patients with PMR develop GCA. However, because the prevalence of GCA is higher in patients with PMR, they should be educated regarding signs and symptoms of GCA.